Belpointe Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
Other funds holding KNSA
Belpointe Asset Management's KNSA Position: Q3 2026 in Review
Belpointe Asset Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 31% in Q3 2026, buying an estimated $84.4K and bringing the position to 4,855 shares worth $362K. The position accounts for 0.01% of the portfolio, ranked #842.
Belpointe Asset Management first reported a position in KNSA in Q4 2022 and has held it in 4 quarters since. 248 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.
- Belpointe Asset Management held 4,855 shares of Kiniksa Pharmaceuticals worth $362K as of Q3 2026.
- Belpointe Asset Management bought 1,146 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $84.4K.
- Kiniksa Pharmaceuticals made up 0.01% of Belpointe Asset Management's portfolio in Q3 2026, its #842 holding.
- Belpointe Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
- 248 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.
Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.